How Federal Regulatory Strategies Are Spurring Innovation in the Use of AI in Cancer Care
In an interview, Travis J. Osterman, DO, MS, FAMIA, FASCO, discusses current regulatory strategies surrounding the use and advancement of AI in oncology practice and the priorities of AI in cancer care for the next several years.
Brief introduction explaining scope and methodology.
#1
Vanderbilt University Medical Center
Nashville, TN
Key Differentiators
Oncology
#2
Vanderbilt-Ingram Cancer Centers
Nashville, TN
Key Differentiators
Oncology
#3
National Comprehensive Cancer Network (NCCN)
Fort Washington, PA
Key Differentiators
Oncology
#4
Dana-Farber Cancer Institute
Boston, MA
Key Differentiators
Oncology
#5
University of California San Diego Moores Cancer Center
La Jolla, CA
Key Differentiators
Oncology
ASCO AI in Oncology
is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in
ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.